New drug JSB462 tested for advanced prostate cancer in japanese patients

NCT ID NCT07174063

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

JSB462 (Luxdegalutamide)

What this could lead to

If safe and effective, this drug could offer a new treatment option for Japanese men with advanced prostate cancer that has spread.

What could go wrong

This is a very early Phase 1 trial with only 15 participants, so it's too soon to know if the drug works. Side effects are unknown and could be serious.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Nagoya, Aichi-ken, 4668560, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138677, Japan

  • Novartis Investigative Site

    RECRUITING

    Koto Ku, Tokyo, 1358550, Japan